The high prevalence of ARID1A mutations in endometriosis‐associated ovarian cancers (EAOCs), which include endometrioid ovarian carcinoma (ENOC) and clear cell ovarian carcinoma (CCOC), has led researchers to attempt to understand its significance with respect to clinical outcomes and the tumour immune microenvironment. This evidence concerns the gene ARID1A and neoplasm.